Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder

Completed · Not applicable · Has a placebo group

Conditions studied: Attention Deficit Hyperactivity Disorder, Substance Abuse

In brief

The purpose of this study is to find out whether atomoxetine (also called Strattera) helps teenagers (12-19) with Attention Deficit Hyperactivity Disorder (ADHD) and drug/alcohol problems.

Key facts

Study ID

NCT00399763

Run by

Denver Health and Hospital Authority

People needed

70

Starts

2005-09-01

Expected to finish

2008-02-01

Last updated by the study team

2015-07-08

Who can join

Age: 12 and older, up to 19. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 12-19
• Provided assent/consent
• attention-deficit hyperactivity disorder (ADHD) by Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS)
• Diagnostic and statistical manual of mental disorders, 4th edition (DSM-IV) checklist <=22
• At least one non-nicotine substance use disorder (SUD) by KSADS
• Plans to live locally for 4 months
• Willing to participate in cognitive behavioral therapy (CBT)

You may not qualify if…

• No mental illness that cannot be managed as an outpatient or without concurrent psychotropic medication
• No allergy to atomoxetine
• No narrow angle glaucoma
• No serious medical illness
• Not pregnant
• Not unwilling to use an effective form of contraception during the trial
• No SUD that cannot be managed as an outpatient or without concurrent psychotropic medication

Where it is running

• Denver Health Medical Center — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.